The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia
Information source: Ortho-McNeil Janssen Scientific Affairs, LLC
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia
Intervention: Paliperidone ER (Drug); Atypical antipsychotics (AAP) (Drug)
Phase: Phase 4
Status: Terminated
Sponsored by: Ortho-McNeil Janssen Scientific Affairs, LLC Official(s) and/or principal investigator(s): Ortho-McNeil Janssen Scientific Affairs, LLC Clinical Trial, Study Director, Affiliation: Ortho-McNeil Janssen Scientific Affairs, LLC
Summary
The purpose of this study is to examine the long-term economic, functional and clinical
outcomes in schizophrenia patients who require a change in antipsychotic treatment, and are
changed to either paliperidone extended release (ER) or another oral atypical antipsychotic
agent (AAP) including aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone.
Clinical Details
Official title: The Paliperidone ER Outcomes Study of Schizophrenia Patients in Typical Clinical Practice
Study design: Observational Model: Cohort, Time Perspective: Retrospective
Primary outcome: Changes in the yearly rate of hospital admissions before and after treatment with paliperidone extended release (ER)
Secondary outcome: Change from baseline in Clinical Global Impression of the severity (CGI-S) scaleChange from baseline in Positive and Negative Syndrome Scale (PANSS) Change from baseline in Personal and Social Performance Scale (PSP and SF-36) Change from baseline in Independent Living Skills Survey (ILSS) Change from baseline in Healthcare and Social Services Resource Utilization Relapse rate Change from baseline in Abnormal Involuntary Movement Scale (AIMS) Change from baseline in Clinical Global Impression of change scale (CGI-C) Change from baseline in Short-Form 36 Health Survey (SF-36) Change from baseline in Medication Compliance with Antipsychotic Medication Change from baseline in Patient Satisfaction with Antipsychotic Medication Changes in safety parameters
Detailed description:
This is a 12-month, retrospective (a study that looks backward in time, usually using
medical records and interviews with patients who are already known to have a
disease)/prospective (a study in which the patients are identified and then followed forward
in time for the outcome of the study), open-label (all people involved know the identity of
the assigned drug) study of clinical, functional and economic outcomes in schizophrenia
patients who require a change in antipsychotic treatment. The patients will be randomly
(study drug assigned by chance like flipping a coin) assigned to receive either
paliperidone extended release (ER) or one of two other prescriber-selected oral atypical
antipsychotic (AAPs). The AAPs include aripiprazole, olanzapine, quetiapine, risperidone,
or ziprasidone. Baseline will be defined as the time when the patient begins to take
paliperidone ER or the other AAP. The study has a "pre/post" design in which paliperidone ER
patients serve as their own controls for the analyses of healthcare utilization. If a
potential patient needs to switch from their current antipsychotic medication they are
eligible for this study. The investigator will determine that the patient may benefit
equally from switching to either paliperidone ER (extended release) or to either of 2 other
antipsychotics. Healthcare use over the 12-month period prior to baseline (the
"pre-period") will be compared to the 12-month period following the start of paliperidone ER
or other AAP (the "post-period"). Data for both periods will be obtained by study
investigators from enrolled patients' medical charts. Patients will continue to be followed
in the study, regardless of change in treatment, until visit 5 at month 12 or if withdrawn
from the study. All patients will receive medical care consistent with local medical
practices.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Must have a clinical diagnosis of schizophrenia for at least 1 year prior to
screening
- Had been receiving treatment with antipsychotics, but is judged to be a candidate for
changing antipsychotic on the basis of either persistent symptoms or continuing side
effects
- Treating physician has determined, before the patient enters the study, that starting
paliperidone extended release (ER) or another of at least two possible atypical
antipsychotics (AAPs) is an appropriate treatment for the patient
- Likely to be managed as outpatient
- Must have signed the informed consent form for DNA pharmacogenomic
Exclusion Criteria:
- Have mental retardation, dementia, bipolar, schizoaffective disorder,
schizophreniform disease, other Diagnostic and Statistical Manual of Mental
Disorders, 4th Edition (DSM-IV) psychiatric disorders or deteriorating neurological
illnesses as determined by clinical evaluation
- Established treatment-resistant schizophrenia, defined as those who have had
treatment failures with adequate trials of two second generation atypicals, previous
treatment with clozapine, or 4 or more hospitalizations in the last 12 months
- History of recent violence or at immediate risk of suicide, or harming self or
others, or of causing damage to property, in the judgment of the investigator
- Patients who are unable to swallow the medication whole
- History or circumstances that may increase the risk of occurrence of torsade de
pointes and/or sudden death in association with the use of drugs that prolong the QTc
interval, including bradycardia, hypokalemia or hypomagnesemia, concomitant use of
drugs that prolong the QTc interval, or presence of congenital long QT syndrome
- Pregnant (as confirmed by urine pregnancy test performed at baseline), planning to
become pregnant, or breast-feeding.
Locations and Contacts
Additional Information
Starting date: April 2007
Last updated: August 28, 2012
|